Name: Latest research reports of Divi's Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 3
Author: Motilal Oswal

Summary	Date	Stock	Author	LTP	Target	Price at reco (Change since reco%)	Upside(%)	Type	Report	Discuss
	12 Sep 2025	Divi's Laboratories	Consensus Share Price Target	6025.00	6362.79	-	5.61	hold	pdf Detailed Estimates
	19 Mar 2023	Divi's Laboratories	Motilal Oswal	6025.00	2620.00	2791.50 (115.83%)		Neutral	pdf post cache	Broker Report Work-in-progress for a better outlook Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	06 Feb 2023	Divi's Laboratories	ICICI Securities Limited Target	6025.00	3024.00	2884.35 (108.89%)	Target met	Hold	pdf post cache	Broker Report Performance weakens, margins shrink ICICI Securities Limited Divi’s Laboratories’ (Divi’s) Q3FY23 performance was well below our estimates. Consolidated revenues fell 7.9% QoQ to Rs17.1bn (I-Sec: Rs20.5bn), EBITDA margin slipped to its lowest-ever at 23.9% (-2,010bps YoY, -960bpsQoQ) pdf Copy Link Share on Share on Share on Share on Alert
	05 Feb 2023	Divi's Laboratories	Prabhudas Lilladhar Target	6025.00	2700.00	2884.35 (108.89%)		Hold	pdf post cache	Broker Report DIVI'S LABORATORIES Prabhudas Lilladhar pdf Copy Link Share on Share on Share on Share on Alert
	04 Feb 2023	Divi's Laboratories	BOB Capital Markets Ltd. Target	6025.00	3200.00	2884.35 (108.89%)	Target met	Hold	pdf post cache	Broker Report Divi's Labs (HOLD): Big miss on revenue and margins BOB Capital Markets Ltd. Q3 disappoints as revenue/PAT of Rs 17bn/Rs 3bn missed consensus by 12%/38% pdf Copy Link Share on Share on Share on Share on Alert
	04 Feb 2023	Divi's Laboratories	Motilal Oswal Reco Target	6025.00	2620.00	2884.35 (108.89%)		Neutral	pdf post cache	Broker Report Lower realization in API sales/ reduced operating leverage drag earnings Motilal Oswal pdf Copy Link Share on Share on Share on Share on Alert
	03 Feb 2023	Divi's Laboratories	ICICI Direct Target	6025.00	2945.00	2884.35 (108.89%)	Target met	Hold	pdf post cache	Broker Report Divi's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
	11 Nov 2022	Divi's Laboratories	SMC online	6025.00		3271.40 (84.17%)		Results Update	pdf post cache	Broker Report Divis Laboratories Limited SMC online pdf Copy Link Share on Share on Share on Share on Alert
	09 Nov 2022	Divi's Laboratories	BOB Capital Markets Ltd. Target	6025.00	3450.00	3298.75 (82.64%)	Target met	Hold	pdf post cache	Broker Report Divi's Labs (HOLD): Disappointing quarter BOB Capital Markets Ltd. Q2 revenue fell 7% YoY to Rs 18.5bn, weighed down by a decline in custom synthesis business pdf Copy Link Share on Share on Share on Share on Alert
	08 Nov 2022	Divi's Laboratories	ICICI Securities Limited Target	6025.00	3893.00	3414.55 (76.45%)	Target met	Accumulate	pdf post cache	Broker Report Margin dips on fall in revenue ICICI Securities Limited Divi’s Laboratories’ (Divi’s) Q2FY23 performance was sharply below our estimates. Consolidated revenue fell 6.7% YoY to Rs18.5bn (I-Sec: Rs22.9bn), EBITDA margin slipped 770bps YoY to 33.5% (I-Sec: 41.2%) and adjusted PAT declined 18.6% YoY to Rs4.9bn (I-Sec: Rs6.2bn). pdf Copy Link Share on Share on Share on Share on Alert
	08 Nov 2022	Divi's Laboratories	ICICI Direct Reco Target	6025.00	3685.00	3414.55 (76.45%)	Target met	Hold	pdf post cache	Broker Report Divi's Laboratories ICICI Direct pdf Copy Link Share on Share on Share on Share on Alert
more loading

Divi's Laboratories Ltd. share price target

Divi's Laboratories Ltd. has an average share price target of 6414.33. The consensus estimate represents an upside of 6.46% from the last price of 6025. View 9 reports from 6 analysts offering long-term price targets for Divi's Laboratories Ltd..

Work-in-progress for a better outlook

Performance weakens, margins shrink

DIVI'S LABORATORIES

Divi's Labs (HOLD): Big miss on revenue and margins

Lower realization in API sales/ reduced operating leverage drag earnings

Divi's Laboratories

Divis Laboratories Limited

Divi's Labs (HOLD): Disappointing quarter

Margin dips on fall in revenue

Divi's Laboratories

Advisor Screeners